Trial Profile
Phase II Open-Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion In Patients With Metastatic, Locally Advanced, or Unresectable Renal Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2005
Price :
$35
*
At a glance
- Drugs DHA-paclitaxel (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 17 Sep 2005 New trial record.